Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) (NCT04954859)
A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Treatment Response in Chronic Hepatitis B Participants With and Without Nucleos(t)Ide Therapy Who Have Participated in a Previous Bepirovirsen Treatment Study
🩺 Plain-English Summary (8th-Grade Level)
This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study and achieved a complete or partial response. Eligible participants will be enrolled in this study after completing the end of study (EoS) visit in the respective parent bepirovirsen studies (studies B-Clear \[209668: NCT04449029\], B-Together \[209348: NCT04676724\], B-Fine \[212602: NCT04544956\], B-Well 1 \[202009: NCT05630807\], B-Well 2 \[219288: NCT05630820\], and TH HBV ASO-001 \[217023: NCT05276297\]). Participants will be categorized as Not-on-NA, NA-cessated, or On-NA based on their nucleos(t)ide analogue (NA) status in the parent study. No further treatment with bepirovirsen will be administered in this study.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Sacramento, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (163 Sites)
Showing the first 25 of 163 sites.
- GSK Investigational Site — Sacramento, California
- GSK Investigational Site — San Jose, California
- GSK Investigational Site — Colorado Springs, Colorado
- GSK Investigational Site — Boston, Massachusetts
- GSK Investigational Site — Detroit, Michigan
- GSK Investigational Site — La Plata, Buenos Aires
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Rosario,
- GSK Investigational Site — Santa Fe,
- GSK Investigational Site — Herston, Queensland
- GSK Investigational Site — Fitzroy, Victoria
- GSK Investigational Site — Aracaju, Sergipe
- GSK Investigational Site — Campinas,
- GSK Investigational Site — Curitiba,
- GSK Investigational Site — Manaus,
- GSK Investigational Site — São Paulo,
- GSK Investigational Site — Vila Mariana,
- GSK Investigational Site — Plovdiv,
- GSK Investigational Site — Sliven,
- GSK Investigational Site — Sofia,
- GSK Investigational Site — Sofia,
- GSK Investigational Site — Sofia,
- GSK Investigational Site — Varna,
- GSK Investigational Site — Calgary, Alberta
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatitis B
- HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B — San Francisco, California
- Entecavir to TAF Switch — Philadelphia, Pennsylvania
- HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B — San Francisco, California
- Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) — Bakersfield, California
- A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease — Orlando, Florida
Explore by condition: All Hepatitis B clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.